Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangtangqi Granule is a traditional Chinese medicine (TCM) hospital preparation developed by the China-Japan Union Hospital of Jilin University. It is specifically formulated for the management of type 2 diabetes mellitus (T2DM). The preparation is typically administered orally in granule form and is often evaluated in clinical settings as an adjunct to standard antihyperglycemic therapies. Its therapeutic goals include improving glycemic control (measured by HbA1c), optimizing lipid profiles, and reducing insulin resistance. In clinical trials, it has been studied in combination with other functional products such as Changle Capsule and Chickpea Natto to assess synergistic effects on diabetic complications and metabolic parameters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tangtangqi Granule.